Two Online Decision Modelling Courses for Health Economists and Health Professionals
The London School of Hygiene & Tropical Medicine and the University of York have partnered to offer two online courses [...]
Syneos Health and Science 37 Announce Partnership Aimed at RWE Integration Into Clinical Trial Design
In an effort to seamlessly incorporate RWE (real world evidence) into clinical trial design, Syneos Health and Science 37 announced [...]
RWD in Action: Determining COVID-19 Reinfection Odds
RWD (real world data) is critical in understanding the likelihood of COVID-19 reinfection. One recent study sought to identify the [...]
Understanding ICER’s New Life Years Metric
ICER (the Institute for Clinical and Economic Review) revealed a new metric in 2018: evLYG (equal value of life years [...]
Comparing ICER and IVI in Shifting Value-Based Reimbursement Landscape
The US healthcare system is transitioning from a volume- to a value-based reimbursement payment structure. Assigning value continues to be [...]
Pharma Price Negotiations and Reimbursement Hurdles in Germany
Negotiating the prices of Advanced Therapy Medicinal Products (ATMPs) is a challenging and convoluted process in Germany. The majority of [...]
The Role of RWE in FDA Regulatory Decisions
RWE (real world evidence) and RWD (real world data) have risen in prominence when it comes to clinical trial design [...]
Preparing for the COVID-19 Economic Impact
The total burden of COVID-19 remains unknown. A toolkit from HMS (Health Management Systems) provides strategies for mitigating underlying issues [...]
Aetion Co-Founder and President Discusses Bias in RWE Studies
One major challenge for researchers utilizing RWE (real world evidence) in their studies is avoiding biases. In contrast, RCTs (randomized [...]
New Survey Results on Impact of COVID-19 on Provider Supply Chains
Advisory Board surveyed 70 professionals in supply chain, financial, and operations roles in US-based healthcare systems. The main goal of [...]
Aurinia Announces ICER’s Favorable Review for Lupus Nephritis Drug
Aurinia Pharmaceuticals announced that ICER (the Institute for Clinical and Economic Review) has released a positive Evidence Report for its [...]
Assigning Value to Cell and Gene Therapies With Analytics
A whitepaper from MMIT provides information on value assessments and insight into market access for gene and cell-based therapies. MMIT [...]
Upcoming Webinar on Managed Care Pharmacy Practices and RWE
A webinar hosted by the AMCP (Academy of Managed Care Pharmacy) will take place on Thursday, April 1st from 2 [...]
Abbvie HEOR Expert Shares Thoughts on RWE and Improving Health Equity
Christopher Boone, Vice President and global head of HEOR (health economics and research outcomes) at Abbvie, recently gave an informative [...]
Why Does Pharma Make Record Profits From Taxpayer-Funded Research? Does Pricing Regulation Really Impact Innovation?
Vaccines have been developed quickly and efficiently since the start of the COVID-19 pandemic, in part due to taxpayer-supported funding. [...]
FDA Reveals Data Modernization Action Plan Including RWD Details
The FDA released DMAP (a Data Modernization Action Plan) in response to changes and trends in the pharma industry. Some [...]
Can RWE Improve Odds in FDA Applications for Medical Devices?
Christian Howell, Vice President and General Manager of Medical Devices and Diagnostics at Aetion, provides insight into when and how [...]
HealthVerity Conversation Provides Insight Into Pharma, RWE, Payers, and COVID-19
Jared Saul, Global Head of Healthcare and Life Sciences Startups at AWS, discusses the healthcare industry with Andrew Goldberg, Co-founder and COO [...]
First Transgender Nominee Confirmed by Senate As Assistant Health Secretary
Rachel Levine has been confirmed to the Senate as assistant health secretary amid bipartisan support. In her previous role, she [...]
Comparing High US Drug Prices to Rest of World is Flawed, Reference Pricing Not a Solution
There are five key points driving high drug prices in the US, including better access in the US and robust [...]
New Review on Inclusion of RWE in Regulatory Decisions
A new paper discusses the state of RWE (real world evidence) and RWD (real world data) in the context of [...]
Fishawack Health Acquires Major HEOR and Market Access Firm PRMA Consulting
Fishawack Health has announced its acquisition of PRMA Consulting, a leading HEOR (health economics and outcomes research) firm with insight [...]
High Powered Computational Tools Are Bringing Changes to Clinical Trial Design
As High-Performance Computing (HPC) becomes more widespread and accessible, even for relatively small companies, clinical trial design is expected to [...]
How Can Payers Outperform the Market?
A new whitepaper details the challenging facing payers in an increasingly competitive market. LexisNexis Risk Solutions recently partnered with HealthcareDive’s [...]
Will the FDA Kill French Dressing? Are Other Salad Dressings Safe?
The FDA (Food and Drug Administration) has announced its intention to edit the accepted definition of French dressing and the [...]